A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Public ClinicalTrials.gov record NCT04196283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT04196283
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- ABBV-181 Drug
- ABBV-368 Drug
- Nab-paclitaxel Drug
- Tilsotolimod Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2020
- Primary completion
- Oct 26, 2022
- Completion
- Oct 26, 2022
- Last update posted
- Feb 26, 2023
2020 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Chicago Medical Center /ID# 217196 | Chicago | Illinois | 60637-1443 | — |
| Norton Cancer Institute /ID# 216179 | Louisville | Kentucky | 40241-2832 | — |
| Barbara Ann Karmanos Cancer In /ID# 214050 | Detroit | Michigan | 48201 | — |
| Nebraska Methodist Hospital /ID# 215786 | Omaha | Nebraska | 68114 | — |
| Atlantic Health System /ID# 216159 | Morristown | New Jersey | 07960-6136 | — |
| Roswell Park Comprehensive Cancer Center /ID# 215882 | Buffalo | New York | 14263 | — |
| Vanderbilt Ingram Cancer Center /ID# 214040 | Nashville | Tennessee | 37232-0021 | — |
| MD Anderson Cancer Center /ID# 214041 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04196283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2023 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04196283 live on ClinicalTrials.gov.